By Vitaliy Katsenelson, CFA
I am not a buyer of Abbott Labs(ABT) at this price, as the margin of safety has been depleted by the latest stock
appreciation. But I like its latest transaction with General Electric (GE). Abbott proved to be a shrewd buyer and seller. It played Johnson & Johnson (JNJ), Guidant (GDT) and Boston Scientific (BSX) masterfully and positioned themselves to be the ”stealth” winner any way that the JNJ/Guidant or Boston Scientific/Guidant acquisition turned.
Diagnostic segment that Abbott is selling to GE for $8.5 billion generates revenues of $2.5 billion and has a 10% EBIT margin, putting a multiple of 34 times operating profits – that’s a nice fat premium – very smart on Abbott’s part. In GE’s defense, it could probably drive some costs out of this business once it combines it with the rest of its medical business.
http://www.contrarianedge.com/
Are You Ahead, or Behind on Retirement?
If you’re one of the over 4 Million Americans set to retire this year, you may want to pay attention. Many people have worked their whole lives preparing to retire without ever knowing the answer to the most important question: am I ahead, or behind on my goals?
Don’t make the same mistake. It’s an easy question to answer. A quick conversation with a financial advisor can help you unpack your savings, spending, and goals for your money. With Zoe Financial’s free matching tool, you can connect with trusted financial advisors in minutes.
Why wait? Click here to get started today!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.